Format

Send to

Choose Destination
Rev Assoc Med Bras (1992). 2017 Mar;63(3):203-206. doi: 10.1590/1806-9282.63.03.203.

Diethylpropion and mazindol: An end to the discussion?

Author information

1
Laboratory of Clinical Services and Evidence in Health, Pharmacy Department, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil.
2
Service of Endocrinology and Metabolism, Hospital de Clínicas, UFPR, Curitiba, PR, Brazil.
3
Department of Pharmaceutical Sciences, Universidade Estadual de Ponta Grossa (UEPG), Ponta Grossa, PR, Brazil.
4
Research Institute for Medicines (iMed.ULisboa), Department of Social Pharmacy, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal.

Abstract

Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa - Agência Nacional de Vigilância Sanitária) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.

PMID:
28489121
DOI:
10.1590/1806-9282.63.03.203
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online
Loading ...
Support Center